icon-account icon-glass

Silenor Withdrawal and Tapering Help

Call us for silenor withdrawal information   


Are you looking for How to Wean Off Silenor?  Need Help for Silenor Withdrawal? Our nonprofit has helped people in 78 countries to safely Come Off Silenor.  We know its more than a slow taper to control Silenor Withdrawal Symptoms, so we take a natural, holistic approach to helping to control Silenor Side Effects and Silenor Withdrawals.  Our 15 years experience, highly skilled team and kind, mentoring approach has made Point of Return the premiere at-home withdrawal program.  Silenor is a Tricyclic Antidepressant that has side effects including fatigue, dizziness, drowsiness, lightheadedness, confusion, agitation, nightmares, anxiety, trouble sleeping, hypomania and confusion. Reducing Silenor slowly minimizes the Silenor Withdrawal Symptoms.  If you would like Help for Silenor Withdrawal,  CONTACT our experts for a free consultation.



Start our silenor withdrawal program  

Our Silenor weaning program is a slow taper that allows you to safely step down from Silenor under the guidance of Our Team, Your Physician and Pharmacist. The Pre-Taper is for Symptom Relief. You will not wean Silenor until you feel better. This is where our Advanced Nutraceuticals are critical. Point of Return provides healthy, Drug-Free Strategies to help ease Silenor withdrawal and support well-being*

Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our In-Home programs are individualized based on your situation. An assessment is done once you start the Silenor Withdrawal Program which allows us to individualize your gameplan based on age; length of time on the medications; health challenges; lifestyle, stress levels; additional medications; and interactions. Don't Wean Silenor alone, work with our Prescription Drug Experts.

Imagine being Free of Silenor Dependency 

- Proven Withdrawal Program completed In-Home with Expert Guidance

- Slowly Taper Silenor

- All-Natural Nutraceuticals to help Ease Silenor Withdrawal

- Professional Information on Interactions

- Free Mentoring on our 24/7 Private Discussion Board

- Free Assessment Upon Starting our Program (a $400 value)




      Mark - Silenor withdrawal help

      "With the regimen of Point of Return's withdrawal program and a slow gradual withdrawal of Remeron, I was drug free within a short period of time.... that was 2 years ago. Thank you God for directing my web fingers to Point of Return." More...


      Mayu - silenor tapering help

      "Today I am alive and I can hold my beautiful son in my arms because of Point of Return's help with their withdrawal program and compassion." More...


      Karen - silenor withdrawal help

      "To those that are beginning this journey; this process is not a walk in the park, but it's achievable and each testimony is someone who walked through your shoes and overcame!" More...


      Each day that comes is filled with renewal, increased strength, and a determination to not let my story go unspoken. Thank you, Point of Return, for the great part you have played in my story of healing. I will remain forever grateful.

      —Miranda (Antidepressant Withdrawal Success Story)

                              using a Natural Approach

      Our team has survived psychoactive drug withdrawal. More...

        We have helped people in 78 countries and in every state of the USA. More...

      We have extensive media coverage; television, print, radio. More...


      Message sent, thanks!

      Silenor Resource Center


      SILENOR HISTORY AND INFO  ( link | pdf )


      Silenor Info and History

      Silenor (Sinequan) is a psychotropic agent with antidepressant and anti-anxiety properties. A study published in JAMA internal Medicine in early 2015 found Silenor (Sinequan)  increased the risk of developing dementia.

      Because Silenor (Sinequan)  also blocks the neurotransmitter Acetylcholine, it is not recommended for patients with a history of glaucoma, increased intraocular pressure or urinary retention. Like all Tricyclic antidepressants, when given in high doses, Silenor (Sinequan)  can induce sinus tachycardia, changes in conduction time and arrhythmias of the heart.

      All Antidepressants can cause withdrawal symptoms if abruptly stopped or tapered too rapidly and Silenor (Sinequan)  is no different. It is recommended to taper slowly.

      Silenor (Sinequan)  is a psychotropic agent with antidepressant and anti-anxiety properties that was developed by Boehringer-Ingelheim, now part of the Roche group. Silenor (Sinequan)  was tested from 1963-1968 in different German and Swiss psychiatric institutions and was approved in Germany initially, then in other countries.

      Silenor (Sinequan)  is a Tricyclic Antidepressant that exerts its action on Serotonin and Norepinephrine but also blocks Dopamine and the histamine receptors. Histamine is involved in the immune response and Dopamine is a critical neurotransmitter that plays important roles in both the brain and body.  Serotonin is primarily found in the gastrointestinal tract, central nervous system and in the blood platelets while Norepinephrine works as both a hormone and a neurotransmitter, stimulating the heart, sweat glands, blood vessels, large internal organs and the adrenals whereas Serotonin is involved in sleep, memory, regulation of the endocrine system, body temperature, mood and behavior and muscle movement.

      Silenor Withdrawal Symptoms, Side Effects, Adverse Reactions


      aggression, anxiety, balance issues , blurred vision, brain zaps, concentration impairment, constipation, crying spells, depersonalization, diarrhea, dizziness. electric shock sensations, fatigue, flatulence, flu-like symptoms, hallucinations, hostility, highly emotional, indigestion, irritability, impaired speech, insomnia, jumpy nerves, lack of coordination, lethargy, migraine headaches / increased headaches, nausea, nervousness, over-reacting to situations, paranoia, repetitive thoughts or songs, sensory & sleep disturbances, severe internal restlessness (akathisia), stomach cramps, tremors, tinnitus (ear ringing or buzzing), tingling sensations, troubling thoughts, visual hallucinations / illusions, vivid dreams, speech or visual changes, worsened depression


      drowsiness, blurred vision, breast development in males, bruises, buzzing or ringing in the ears, changes in sex drive, chills, confusion, constipation, diarrhea, difficulty urinating, disorientation, dizziness, dry mouth, enlarged breasts, fatigue, fluid retention, flushing, fragmented or incomplete movements, hair loss, hallucinations, headache, high fever, high or low blood sugar, inappropriate breast milk secretion, indigestion, inflammation of the mouth, itching and skin rash, lack of muscle control, loss of appetite, loss of coordination, low blood pressure, nausea, nervousness, numbness, poor bladder control, rapid heartbeat, red or brownish spots on the skin, seizures, sensitivity to light, severe muscle stiffness, sore throat, sweating, swelling of the testicles, taste disturbances, tingling sensation, tremors, vomiting, weakness, weight gain, yellow eyes and skin  


      Severe: seizures, agranulocytosis, hepatic failure, hyperkalemia, serotonin syndrome, AV block, bone fractures, suicidal ideation, ileus, heart failure, myocardial infarction, torsade de pointes, ventricular tachycardia, stroke, vasculitis, SIADH, bronchospasm, ocular hypertension

      Moderate: dysarthria, contact dermatitis, hypertension, dystonic reaction, pseudoparkinsonism, dyskinesia, chest pain (unspecified), edema, anemia, leukopenia, eosinophilia, thrombocytopenia, hyperthyroidism, goiter, hypothyroidism, diabetes mellitus, wheezing, dysuria, hepatitis, elevated hepatic enzymes, jaundice, hypermagnesemia, sinus tachycardia, ST-T wave changes, palpitations, hematoma, dyspnea, hyperbilirubinemia, hypokalemia, blepharospasm, constipation, orthostatic hypotension, impotence (erectile dysfunction), ejaculation dysfunction, urinary retention, blurred vision, withdrawal, memory impairment, migraine, peripheral neuropathy, ataxia, EEG changes, mania, depression, hallucinations, psychosis, hostility, delirium, akathisia, confusion, complex sleep-related behaviors, parotitis, glossitis, stomatitis, PR prolongation, QT prolongation, peripheral edema, galactorrhea, testicular swelling, erythema, hyperglycemia, hyponatremia / Delayed / Incidence not knownhypoglycemia, cycloplegia, hyperthermia

      Mild: skin irritation, yawning, fatigue, nausea , appetite stimulation, hyperhidrosis, flushing, pharyngitis, syncope, insomnia, asthenia, nightmares, paresthesias, anorexia, dysgeusia, abdominal pain, gastroesophageal reflux, vomiting, diarrhea, alopecia, pruritus, pallor, rash, purpura, laryngitis, nasal congestion, sinusitis, infection, nocturia, arthralgia, myalgia, back pain, folliculitis, chills, cough, influenza, rhinorrhea, muscle cramps, diplopia, xerophthalmia, ocular pain, tinnitus, otalgia, lethargy, drowsiness, dizziness, xerostomia, dyspepsia, weight gain, headache, tremor, anxiety, irritability, agitation, restlessness, pyrosis (heartburn), tongue discoloration, libido decrease, breast enlargemen, dysmenorrhea, gynecomastia, petechiae, photosensitivity, urticaria, fever, increased urinary frequency, mydriasis


      Children, suicidal ideation

      The safety and efficacy of doxepin for the treatment of depression and/or anxiety in children under 12 years of age have not been established. The safety and efficacy of low-dose doxepin when used as a hypnotic agent, have not been established in children and adolescents under the age of 18 years old. Use of doxepin cream in pediatric patients is not recommended, due to the potential for systemic absorption and adverse effects; one case of toxicity has been reported in a young child. In October 2004, the FDA directed manufacturers of all antidepressants to include a boxed warning detailing the risk of suicide in pediatric patients. A causal role has been established for antidepressants in inducing suicidality in pediatric patients. The risk of suicidality for these drugs was identified in a pooled analysis of 24 placebo-controlled trials (n = 4,400) lasting up to 16 weeks in pediatric patients with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders. The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants (SSRIs and others). The average risk of such events on drug was 4% and 2% for placebo; however, no suicides occurred in these trials. Pooled analysis of short-term clinical trials during early phase treatment with SSRIs and other antidepressants in young adults (18 to 24 years) also showed an increased risk of suicidal thinking and behavior. The clinical need for an antidepressant in children or young adults for any use must be weighed against the risk of increased suicidality; patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior, particularly within the first few months of starting therapy or at the time of dose increase or decrease; such observation would generally include at least weekly face-to-face contact with patients during the first 4 weeks of treatment, then every other week visits for the next 4 weeks, then at 12 weeks, and as clinically indicated beyond 12 weeks; additional contact by telephone may be appropriate between visits. It is unknown if the suicidality risk in children or young adults extends to longer-term therapy (i.e., beyond several months). The possibility of a suicide attempt is inherent in patients with depressive symptoms, whether these occur in primary depression or in association with another primary psychiatric disorder. All patients with a history of suicidal ideation or behaviors and those with a prominence of suicidal ideation prior to treatment are considered at an increased risk for suicidal ideation or attempts, and should be closely monitored during treatment with doxepin. In primarily depressed patients, worsening of suicidal thoughts, including suicidal ideation, has occurred in association with hypnotic use; caution is also advisable when using low-dose doxepin as a hypnotic agent. The risk of suicidal ideation in children, adolescents, and young adults from the use of low-dose doxepin as a hypnotic agent is unknown but cannot be excluded. In patients who exhibit changes in symptoms, worsening of depression or emergent suicidality, a decision should be made to change or discontinue treatment. If discontinuing, the medication should be tapered as rapidly as possible, but with recognition that abrupt discontinuation can also cause adverse symptoms. Tricyclic antidepressants (TCAs) should be prescribed in the smallest quantity consistent with good patient management in order to reduce the risk of overdose.

      Silenor References and Information

      According to the FDA:

      Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms.

      Withdrawal Symptoms: The possibility of development of withdrawal symptoms upon abrupt cessation of treatment after prolonged SINEQUAN (Silenor) administration should be borne in mind. These are not indicative of addiction and gradual withdrawal of medication should not cause these symptoms.




      *While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.

      *The statements/info on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.

      * Testimonial results may vary person to person.

      *The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized With Your physician to help you with your drug withdrawal process and with his or her consent and support throughout.

      *This program is not meant to cure or prevent any disease or illness.

      *Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support throughout the process. More..